Effects of species differences on oocyte regulation of granulosa cell function

Jia Yi Lin, Janet L Pitman-Crawford, Adrian H Bibby, Norma L Hudson, C Joy McIntosh, Jennifer L Juengel¹ and Kenneth P McNatty

School of Biological Sciences, Victoria University of Wellington, Wellington 6140, New Zealand and ¹Centre for Reproduction and Genomics, Invermay Agricultural Centre, AgResearch Limited, Mosgiel 9053, New Zealand

Correspondence should be addressed to K P McNatty; Email: kenneth.mcnatty@vuw.ac.nz

Abstract

The aims were to investigate whether oocyte-secreted growth factors from a high (i.e. rat) and low (i.e. sheep) ovulation rate species could stimulate ³H-thymidine incorporation in granulosa cells (GC) from antral follicles from the same or across species. Denuded oocytes (DO) were co-incubated with GC with or without specific antibodies to growth differentiating factor 9 (GDF9) or bone morphogenetic protein 15 (BMP15). Co-incubations of DO-GC from the same or across species significantly increased thymidine incorporation in GC with increasing numbers of DO. GDF9 immuno-neutralisation reduced thymidine incorporation in rat GC co-incubated with either rat or ovine DO and in ovine GC co-incubated with ovine or rat DO. BMP15 immuno-neutralisation only reduced thymidine incorporation when ovine DO were co-incubated with either ovine or rat GC. Western blotting of oocytes co-incubated with GC identified GDF9 and BMP15 proteins for sheep and GDF9 protein for rats in oocyte lysates and incubation media. With respect to rat BMP15, a promature protein was identified in the oocyte lysate but not in media. Expression levels of GDF9 relative to BMP15 mRNA in DO co-incubated with GC were highly correlated ($R^2 = 0.99$) within both species. However, the expression ratios were markedly different for the rat and sheep (4.3 vs 1.0 respectively). We conclude that during follicular development, rat oocytes secrete little, if any, BMP15 and that GDF9 without BMP15 can stimulate proliferation of rat and ovine GC. In contrast, ovine oocytes secrete both BMP15 and GDF9, and both were found to stimulate proliferation in ovine and rat GC.

Introduction

Recent in vitro studies using recombinant growth differentiation factor 9 (GDF9) and/or bone morphogenetic protein 15 (BMP15) have shown that these growth factors have a greater than additive (i.e. cooperative) effect on thymidine incorporation in granulosa cells (GC; McNatty et al. 2005a, 2005b, McIntosh et al. 2008, Mottershead et al. 2011). Furthermore, it has been established that these oocyte-derived growth factors are essential regulators of ovarian follicular growth and ovulation rate (i.e. the number of follicles ovulated during an oestrous or menstrual cycle) (Dong et al. 1996, Galloway et al. 2000, Di Pasquale et al. 2004, Hanrahan et al. 2004, McNatty et al. 2005c, Otsuka et al. 2011). The evidence in sheep and rodents, as in other species such as pig, deer and cow, is that GDF9 and BMP15 mRNA are expressed in oocytes and not in cumulus cells (Crawford et al. 2011, Crawford & Mcnatty 2012). Moreover, GDF9 is expressed in oocytes from the primordial stage in both sheep and rodents whereas BMP15 is expressed only from the primary stage of growth. Both genes continue to be expressed in oocytes throughout follicular development (Dube et al. 1998, Jaatinen et al. 1999, Galloway et al. 2000, Shimasaki et al. 2004, Juengel & McNatty 2005). Immuno-neutralisation studies in sheep show that, in this species, GDF9 and BMP15 are essential for the proliferation of GC during preantral as well as antral follicular development (McNatty et al. 2007, Juengel et al. 2002). Moreover, the expression of GDF9 and BMP15 mRNA remains essentially unchanged during antral follicular growth until shortly after the preovulatory LH surge in sheep and other species (Prochazka et al. 2004, Feary et al. 2007, Crawford et al. 2011, Mester et al. 2011). In rodents, recombinant human BMP15 has been shown to be a potent growth factor when either added to rat GC in vitro (Otsuka et al. 2000, Moore et al. 2003) or over-expressed in mice (McMahon et al. 2008). However, the proregion of mouse BMP15 inhibits the efficient post-translational processing of BMP15 such that under normal physiological conditions the levels of secreted protein are thought to be low (Hashimoto et al. 2005), at least until the preovulatory...
surge of gonadotrophins (Yoshino et al. 2006). Thus, although variations in biologically active levels of GDF9 and/or BMP15 can increase or decrease ovulation rate (Dong et al. 1996, Galloway et al. 2000, Yan et al. 2001, Juengel et al. 2002, McNatty et al. 2007, Otsuka et al. 2011, McIntosh et al. 2012), it has been proposed that it is the physiological levels of secreted BMP15 protein which may be a key difference between animals with a low or high ovulation rate phenotype (McNatty et al. 2004, Moore et al. 2004).

The primary targets of GDF9 and BMP15 action are the cumulus and GC (see Otsuka et al. (2011) for review). One approach to examining the effects of species differences of oocytes on GC is to test the effects of oocytes from a high ovulation rate phenotype against GC from a low ovulation rate phenotype and vice versa. Hitherto, the oocyte–GC co-incubation model has been used extensively to determine the roles of oocytes or oocyte-derived growth factors on the regulation of GC function (Vanderhyden et al. 1992, Lanuza et al. 1998, Otsuka & Shimasaki 2002, Gilchrist et al. 2004). This model has also been used to test the role of GDF9 from murine oocytes on murine GC using an immuno-neutralisation approach with a GDF9-specific MAB (Gilchrist et al. 2004). However, the application of this co-incubation model to evaluate the roles of both BMP15 and GDF9 in different ovulation rate phenotypes has, to our knowledge, not been undertaken hitherto.

The aim of this study was to test in vitro whether a key difference between a low (i.e. sheep) and a high (i.e. rat) ovulation rate species relates, at least in part, to differences in the role of oocytes and their secretions of GDF9 and BMP15 on GC activity. The hypothesis being tested was that while oocytes from rats and sheep would stimulate DNA synthesis and thus cell proliferation in GC from the same species, rat oocytes would not secrete sufficient BMP15 to cooperate with GDF9 to stimulate DNA synthesis in ovine GC. In contrast, sheep oocytes would secrete sufficient levels of both GDF9 and BMP15 to stimulate rat GC. The key endpoints used in these denuded oocyte (DO) and GC in vitro co-incubation studies within and across species were as follows: 3H-thymidine incorporation by GC as a marker of DNA synthesis and cell proliferation (Juengel et al. 2006) in the presence or absence of specific antibodies to GDF9 or BMP15; the molecular forms of GDF9 and BMP15 proteins present within, and/or secreted from, oocytes in vitro; and the levels of BMP15 and GDF9 mRNA expression in oocytes co-incubated with GC.

**Results**

**Effect of numbers of DO on 3H-thymidine incorporation by GC**

There were significant effects of increasing numbers of oocytes on 3H-thymidine incorporation by rat or ovine GC when co-incubated with DO derived from the same species (Fig. 1A and B). When rat DO were co-incubated with sheep GC (Fig. 2A) or when sheep DO were co-incubated with rat GC (Fig. 2B), there were also significant effects of increasing numbers of oocytes on the mean level of 3H-thymidine incorporated by GC.

**Effect of GDF9 or BMP15 immuno-neutralisation on 3H-thymidine incorporation by GC after co-incubation with DO**

These data are summarised in Fig. 3. All values shown are expressed relative to the fold increase following co-incubation of DO and GC without antibody present (assigned a value of 1). The mean ratios for the non-specific antibody controls were not significantly different from the controls in which no antibody was added. Immuno-neutralisation of GDF9 protein with a GDF9 MAB during co-incubation of rat DO with either rat or ovine GC or of ovine DO with either ovine or rat GC resulted in significant reductions in 3H-thymidine incorporation by GC compared with that for the non-specific antibody (Fig. 3A). Immuno-neutralisation of BMP15 protein following ovine DO co-incubation with either ovine or rat GC showed significantly reduced levels of 3H-thymidine incorporation. However, there was no significant change in 3H-thymidine incorporation when rat DO were co-incubated with rat or ovine GC (Fig. 3B).

![Figure 1](image-url) Effects of differing numbers of denuded oocytes (DO) on 3H-thymidine incorporation (c.p.m.) by granulosa cells (GC) after co-incubations of (A) rat DO with rat GC or (B) ovine DO with ovine GC. Histograms represent geometric mean ± 95% confidence limits from nine to ten replicate experiments. Histograms not sharing a common alphabetical superscript are significantly different (P<0.05).
these molecular forms of GDF9 was confirmed by blocking studies, where the antibody was preadsorbed with *Escherichia coli*-derived ovine GDF9 (Fig. 5B, lanes 1 and 2). In sheep, both premature and mature GDF9 protein forms were detected in the oocyte lysate (Fig. 6A, lane 1) and the mature form of GDF9 protein was predominant in the incubation media (Fig. 6A, lane 2). These molecular forms of GDF9 were blocked by preadsorption of the antibody with *E. coli*-derived ovine GDF9 (Fig. 6B). With respect to BMP15, a premature band of 49 kDa size was identified in rat oocyte lysate by two different BMP15 MABs (Fig. 7A, lane 1; C, lane 1). This 49 kDa band was specific for BMP15 as it could be blocked by preadsorption of the antibody with *E. coli*-derived ovine or mouse BMP15 (Fig. 7B and D, lane 1 respectively). With the Mab3A/A, but not 61A, BMP15 antibody trace levels of the mature BMP15 form of the rat BMP15 reference material could be detected but no convincing evidence for a mature form of BMP15 could be detected in the rat oocyte lysate. There was no evidence of the 49 kDa or mature protein band in the incubation media from rat oocytes (data not shown). For ovine BMP15, both a premature

---

**Effect of BMP15 immuno-neutralisation on \( ^{3}H \)-thymidine incorporation by GC after co-incubation with recombinant GDF9 and BMP15**

The ability of the BMP15 antibody (Mab61A) to immuno-neutralise recombinant rat (r) BMP15 is shown in Fig. 4. All values shown are expressed relative to the fold increase following co-incubation of recombinant ovine (o) GDF9+ rBMP15 with rat GC (assigned a value of 1). Recombinant oGDF9 or rBMP15 alone did not stimulate \( ^{3}H \)-thymidine uptake in rat GC above background levels (data not shown). Uptake of \( ^{3}H \)-thymidine in GC was not different following the addition of a control antibody (PAB1) together with oGDF9 + rBMP15, relative to the addition of recombinant oGDF9 + rBMP15 without antibody (\( P>0.05 \)). Mab61A significantly suppressed the ability of recombinant oGDF9+ rBMP15 to stimulate \( ^{3}H \)-thymidine incorporation by GC relative to that of PAB1 antibody (\( P<0.01 \)).

**GDF9 and BMP15 western blotting studies**

To detect the different molecular forms of GDF9 and BMP15 proteins present in oocytes and incubation media, western blotting was performed under reducing conditions. In the rat, mature forms of GDF9 protein were evident in the oocyte lysate and incubation media (Fig. 5A, lanes 1 and 2 respectively). The specificity of
and a mature form of the protein were present in the oocyte lysate (Fig. 8A, lane 1) whereas only the mature form was noted in the incubation media (Fig. 8A, lane 2). The blocking study using an E. coli-derived ovine BMP15 mature protein confirmed that these protein bands were specific for BMP15 (Fig. 8B, lanes 1 and 2).

**BMP15 and GDF9 gene expression in DO during co-incubation with GC**

These data are summarised in Fig. 9. There were no changes in expression levels of Gdf9 and Bmp15 mRNA in rat DO during the first 8 h of co-incubation with rat GC. However, after 24-h co-incubation, the mean expression levels of both genes had declined by ~75% (P ≤ 0.05 for Gdf9 and P ≤ 0.052 for Bmp15) compared with those values at 0 h (Fig. 9A). When the cycle threshold values for Bmp15 and Gdf9 of individual rat DO were compared over the 0-, 8- and 24-h co-incubation period, a significant linear relationship was identified (Fig. 9B; P < 0.001; R² = 0.9953). The overall mean Gdf9 mRNA expression level in the rat was 4.32 ± 0.14 times that of Bmp15 mRNA. In contrast, the relative expression levels of GDF9 and BMP15 mRNA remained unchanged in ovine DO throughout the entire co-incubation period with ovine GC (Fig. 9C). When the cycle threshold values for BMP15 and GDF9 mRNA for individual ovine DO were compared over the incubation interval, a significant linear relationship was also identified (Fig. 9D; P < 0.001; R² = 0.9968). The overall mean GDF9:BMP15 mRNA expression ratio was 1.03 ± 0.02.

**Discussion**

The key finding from this in vitro study was that the oocyte-derived paracrine signalling system in rats and sheep differs in the way it influences GC activity. Of the two growth factors investigated in this study, namely GDF9 and BMP15, both ovine-secreted factors from the oocyte were required by ovine GC to enhance 3H-thymidine incorporation and thus DNA synthesis in vitro. In contrast for the rat, only rat GDF9 was required by rat GC to enhance 3H-thymidine incorporation. This is consistent with the in vivo evidence from results in BMP15-KO mice (Yan *et al.* 2001), indicating that BMP15 is not a critical growth factor for follicle development in rodents. Of interest was the finding that rat oocyte-derived GDF9 without rat BMP15 was able to stimulate 3H-thymidine incorporation in ovine GC. Furthermore, both the ovine oocyte-secreted factors GDF9 and BMP15 were essential to stimulate 3H-thymidine incorporation in rat GC. These species differences are likely to be due to both the levels of protein secreted and the bioactivity of the different protein forms (McNatty *et al.* 2005a, 2005b, Simpson *et al.* 2012).

There was a dose response effect of numbers of ovine or rat oocytes on 3H-thymidine incorporation by GC of either species. These findings are consistent with their known roles on ovarian follicular development in vivo (Juengele & McNatty 2005). Collectively, the aforementioned results are consistent with previous reports showing dose-related effects of mouse, rat or bovine oocytes on 3H-thymidine incorporation by rodent GC (Vanderhyden *et al.* 1992, Lanuza *et al.* 1998, Otsuka & Shimasaki 2002, Gilchrist *et al.* 2004, 2006). Despite a dose response effect of rat oocyte numbers on 3H-thymidine incorporation by rat GC, 3H-thymidine incorporation in rat DO-GC co-incubations was only reduced after blocking the action of GDF9 and not of BMP15. Moreover, despite rat DO causing at least a

![Figure 4](image-url) Relative uptake of 3H-thymidine by rat granulosa cells (GC) in the presence of recombinant ovine (o) GDF9 plus recombinant rat (r) BMP15 with a non-specific MAB PAB1 (MabPAB1) or a MAB to BMP15 (Mab61A). The dotted line indicates the background c.p.m. of 3H-thymidine by GC without oGDF9 + rBMP15 relative to wells with oGDF9 + rBMP15 without antibody. The median (range) c.p.m. of 3H-thymidine uptake by GC in the oGDF9 treatment without antibody was 914 (350–1825). n = 4 experiments. **P < 0.01.

![Figure 5](image-url) Western immunoblots of GDF9 in (A) rat oocyte lysate and incubation medium and (B) after the GDF9 antibody (Mab47B) was preadsorbed with an E. coli-derived ovine or rat GDF9 mature protein. Molecular sizes are indicated on the left of (A). Lanes are as follows: 1 = oocyte lysate, 2 = medium in which oocytes were incubated (incubation medium), 3 = transfected 293H cell produced rat BMP15 for cross-reactivity and 4 = transfected 293H cell produced mouse GDF9 as a positive control.
A threefold increase in thymidine incorporation in sheep GC, only immuno-neutralisation of GDF9, and not BMP15, inhibited thymidine uptake. It could be argued that the failure of the BMP15 antibody to neutralise rat oocyte-derived BMP15 was due to the low sequence homology (i.e. 27%) between the rat BMP15 mature protein and the MAB (Mab61A) used in this study. However, this seems unlikely to be the case as Mab61A was effective at blocking the effect of recombinant rBMP15 on 3H-thymidine uptake by rat GC exposed to both recombinant rBMP15 and oGDF9; in this experiment, recombinant rBMP15 or oGDF9 alone was unable to stimulate 3H-thymidine uptake by rat GC. As GDF9 and BMP15 were the only factors investigated, it is not possible to rule out critical roles for other putative oocyte-derived growth factors such as BMP6 or FGF8 (Juengel et al. 2006, Sugiura et al. 2007).

It is worth noting that there was considerable variation in 3H-thymidine uptake by GC between individual rat and sheep DO-GC co-incubation experiments when oocyte numbers were titrated. This is likely to be due to at least three factors that are not able to be controlled. The first relates to the fact that at any moment in time, no two follicles are likely to be functionally identical (McNatty et al. 2010), resulting in each DO pool containing functionally variable populations of DO. This was in contrast to the GC component in the co-incubation studies where identical aliquots of a pooled preparation of GC were added to all the incubation wells. In light of this, the second uncontrolled factor relates to the synergistic effects of GDF9 and BMP15. Previous studies show that very small changes in the level of recombinant BMP15 relative to GDF9 protein, or vice versa, can cause large changes (e.g. sevenfold) in 3H-thymidine uptake by GC (McNatty et al. 2005a). A third contribution to the variability observed in the present experiments is likely to be due to the relative proportions of healthy and degenerate oocytes recruited for study. While obviously degenerate oocytes were removed before denuding, no other criteria were used for exclusion. However, it is known that when the health of follicles based on GC criteria is assessed, BMP15 and GDF9 mRNA are significantly lower in atretic compared with healthy follicles (Crawford et al. 2011). Moreover, Lanuza et al. (1998) have reported that poor quality bovine oocytes are less effective than good quality oocytes in stimulating 3H-thymidine uptake by rat GC.

The immuno-neutralisation experiments established that of the two specific growth factors tested, ovine GC require both ovine GDF9 and ovine BMP15 to stimulate thymidine incorporation in contrast to rat GC, which

---

**Figure 6** Western immunoblots of GDF9 in (A) ovine oocyte lysate and incubation medium and (B) after the GDF9 antibody (Mab37A) was preadsorbed with an ovine E. coli-derived GDF9 protein. Molecular sizes are indicated on the left of (A). Lanes are as follows: 1 = oocyte lysate, 2 = medium in which oocytes were incubated, and 3 = 293H cell produced ovine GDF9 as a positive control.

**Figure 7** Western immunoblots of BMP15 in (A and C) rat oocyte lysate and (B and D) after the BMP15 antibody (Mab61A in B and Mab3A/A in D) were preadsorbed with E. coli-produced ovine BMP15 and mouse BMP15 for Mab61A and Mab3A/A respectively. Molecular sizes are indicated on the left of (A) and (C). Lanes are as follows: 1 = oocyte lysate, 2 = transfected 293H cell-produced rat BMP15-positive control and 3 = transfected 293H cell-produced ovine BMP15 as a positive control. The high MW bands in the preadsorbed blots B & D were not identified. The separation of lanes 2 & 3 in all figures indicates the excision of a lane for a protein not relevant to this study.
require rat GDF9 but not rat BMP15. This interpretation is consistent with our hypothesis, namely, that there is no effect of BMP15 immuno-neutralisation on thymidine incorporation by rat or sheep GC co-incubated with rat DO due to species of origin of the growth factors (McNatty et al. 2005b). It is also consistent with the recent report by Simpson et al. (2012) which showed that there are species differences in the bioactivity of GDF9 due to different amino acid residues at key positions with respect to receptor binding domains. For example, through site-specific mutagenesis, they report that the Gly391 residue in the mature domain in human GDF9 confers latency whereas in mouse and rat GDF9, the 391 residue is Arg instead of Gly, which presents GDF9 in an active form. Interestingly, ovine GDF9 contains the Gly residue at 391, indicating that ovine GDF9 is not biologically active. In this and previous studies, we have reported that recombinant oGDF9 was not biologically active in stimulating 3H-thymidine uptake by rat GC (McNatty et al. 2005a).

It was of interest to note that the stimulatory effects of ovine DO on rat GC could be inhibited in part, by the BMP15 antibody indicating that BMP15 is capable of stimulating thymidine incorporation in the rat when present with oocyte-derived GDF9 in the incubation media. This is consistent with previous reports that 3H-thymidine uptake rat GC can be stimulated by recombinant human BMP15 in vitro (Otsuka et al. 2000, Moore et al. 2003, McMahon et al. 2008). However, we cannot exclude the possibility that the recombinant rBMP15 used may differ in bioactivity from endogenous rat BMP15. In addition, it is not possible to completely rule out the existence of trace levels of rat BMP15 in the co-incubation media as unprocessed promature BMP15 was detected in rat oocytes, although not in the media. Recent studies by McIntosh et al. (2012) demonstrated that immuno-neutralisation of the proregion of mouse BMP15 significantly reduced both ovulation rate and litter size of mice, suggesting that even secreted forms of promature BMP15 have a biological role. However, as mentioned above, the roles of other oocyte-secreted factors cannot be discounted.

Promature and/or mature forms of GDF9 were present in oocyte lysates from rats and sheep. In both these species, fully processed monomeric forms of GDF9 were present in the incubation media. With respect to BMP15, oocyte lysates from sheep contained both promature and mature forms of the protein with a secreted fully processed mature form in the incubation media.
In contrast, in the rat using the same antibody (Mab61A), a BMP15 promature form was present in the oocyte lysate, but there was no evidence of mature forms in either oocyte lysate or 293-derived recombinant rBMP15 control. No evidence was found for any secreted form of BMP15 in the incubation media notwithstanding the presence of very large numbers of oocytes in the incubation media (data not shown). Using an alternative MAB (Mab3A/A) that recognises both the promature and the mature forms of recombinant rBMP15, only trace levels of promature but not mature forms of BMP15 were identified in rat oocyte lysates. Using the Mab3A/A antibody, there was also no evidence that rat oocytes secreted any form of BMP15 into the media (data not shown). Of interest is that the predominant form of recombinant rBMP15 was the promature protein. When this preparation of rat BMP15 was added with ovine GDF9, the two proteins together enhanced thymidine uptake by rat GC. This finding is consistent with that reported by McIntosh et al. (2008), demonstrating a role for the proregion of BMP15 in the co-operative actions of GDF9 and BMP15 on rodent GC.

Overall, the results from the western blotting studies suggest that, compared with sheep, rat oocytes secrete relatively little BMP15. This interpretation is further supported by the preadsorption experiments whereby the addition of BMP15 antibodies did not reduce the increase in thymidine incorporation by rat GC after the addition of rat DO.

It could also be argued that the reason why rat oocytes secreted insufficient BMP15, not withstanding the large numbers of oocytes, arose from a decline in Bmp15 mRNA expression levels by the end of the incubation period. However, the lower mean Bmp15 mRNA levels after 24 h were matched by an equivalent decline in Gdf9 mRNA levels, yet there was sufficient GDF9 in the spent media to stimulate thymidine incorporation in rat GC as the GDF9 effect could be neutralised by the addition of a GDF9 MAB. In contrast to the rat, there was no change in GDF9 and BMP15 mRNA expression in DO from sheep at the end of the incubation period. However, perhaps of greater significance in this regard were the relative mRNA expression ratios of GDF9 and BMP15 in the two species. In sheep, the relative mRNA expression levels of GDF9 were equivalent to those of BMP15 whereas in the rat the relative mRNA expression levels of Gdf9 were 4.3-fold greater than those of Bmp15. Thus, it seems reasonable to propose that a key difference between oocytes in the two species is that BMP15 and GDF9 mRNA are expressed in equivalent amounts in sheep, resulting in the secretion of appreciable amounts of both proteins, whereas in rats the relative mRNA expression levels of Bmp15 are low compared with Gdf9, resulting in appreciable amounts of GDF9 but limited amounts of mature BMP15 being secreted. In this study, the gene expression data were generated from pools of sheep or rat oocytes.

Nevertheless, the results are consistent with previous reports based on expression levels in individual oocyte–cumulus cell complexes and DO (Crawford et al. 2011, Crawford & McNatty 2012).

The results from this study also support the in vivo findings by Crawford & McNatty (2012) by demonstrating that the mRNA expression levels of GDF9 and BMP15 in DO of sheep and rats in vitro are also strongly associated. In vivo, the Gdf9:Bmp15 expression ratios are tightly regulated and differ across a wide range of species (e.g. mouse, cattle, pig and deer; Crawford & McNatty 2012). Linear regression analyses of both the sheep and the rat DO also show that the expression ratios of GDF9:BMP15 remain unchanged over the incubation period. While the removal of the cumulus cells was necessary to standardise the testing of effects of oocytes on GC thymidine incorporation, it is reasonable to suppose that removal of the somatic cells may compromise the functional state of the oocytes incubated in vitro, as was observed for the rat. Under normal physiological conditions, the expression levels of BMP15 and GDF9 in healthy ovine follicles between 1 and 5 mm in diameter are not related to antral follicular development (Crawford et al. 2011).

This in vitro study confirms and extends our understanding of the species differences in the relative roles of GDF9 and BMP15. This study also supports the hypothesis that in vivo, in a low ovulation rate species such as sheep, oocytes express levels of BMP15 mRNA equivalent to or greater than that of GDF9 and secrete biologically active levels of BMP15 protein. They also support the notion that during follicular growth, both GDF9 and BMP15 are required to promote cell proliferation in a low ovulation rate species. By contrast, in a high ovulation rate species such as the rat, Gdf9 mRNA is expressed at relatively higher levels than Bmp15 mRNA and little, if any, BMP15 protein is secreted at least until the preovulatory LH surge.

Materials and Methods

In order to compare the possible roles of oocyte-derived GDF9 and BMP15 on GC activity, the number of DO was titrated against a fixed number of GC. This determined the optimal number of DO that caused a significant uptake of $^3$H-thymidine, as a measure of DNA synthesis, in GC of both species. This optimal DO number was then used for subsequent immuno-neutralisation and gene expression studies. For the western blotting studies, the numbers of oocytes recovered were 100–500 per 50 µl of incubation media.

Oocyte collection

Ovaries from pre-pubertal ewe lambs were collected from the slaughterhouse (Taylor Preston, Ngauranga, Wellington, New Zealand) and transported on ice to the laboratory. Thereafter, at room temperature, the ovaries were trimmed of oviductal
respectively and incubated for 16 h. Thereafter, the levels of transcription were transferred into 96-well plates in 30 and 20 μl of the appropriate number of DO and 20,000 live GC were added to each test well together with 5 μl of the appropriate antibody. The addition of 20 μl of M199 media containing 32 DO were added to each test well together with 5 μl of the appropriate antibody. The addition of 20 μl of M199 media containing 20,000 GC resulted in a final volume of 55 μl/well. The antibodies tested were MABs specific for either GDF9 (Mab47B) or BMP15 (Mab61A, Mab3A/A) or a control MAB against a nematode antigen (MabPAB1). Control wells containing DO with GC but no antibody or GC without DO were included in each incubation experiment. The Mab47B antibody was made against the ovine GDF9 mature protein sequence SEYFKQFLFQNEC, which has 100% sequence homology with mice. This sequence also has a 93% homology with the corresponding rat sequence (SEYFRQFLFQNEC). Moreover, this antibody has previously been used for immunoneutralisation studies of GDF9 in vitro and the antibody does not cross-react with BMP15 (McIntosh et al. 2008). The Mab61A antibody against BMP15 was generated after immunization of mice against an E. coli-derived sheep BMP15 mature protein and found to be effective in immunoneutralisation studies in sheep and not to cross-react with GDF9 (McNatty et al. 2005a). From peptide mapping studies, the MAB appears to be directed against an N-terminal sequence on the mature protein sequence, QAGSIASEVPGPSQ (unpublished data; amino acid differences in bold). This sequence has a 64% homology with the corresponding rat BMP15 sequence, QTCGIASDVPCPSQ (amino acid differences are in bold). However, there are four homologous amino acids in a row (italicised) and previous studies with BMP15 and GDF9 antibodies indicate that a 27% homology can be sufficient for antibody recognition of ligand (McNatty et al. 2007). To validate the efficacy of the Mab61A antibody to immuno-neutralise rat BMP15, a 293-derived recombinant αGDF9 (66 ng/ml; McNatty et al. 2005a) and 293-derived recombinant rBMP15 (6.5 ng/ml) were either added alone or together with rat GC; these experiments were performed without antibody, with the control (PAB1) antibody (3.4 μg/ml) or with Mab61A (3.4 μg/ml) as described earlier (n=4 replicate experiments). In all experiments involving measures of 3H-thymidine incorporation, the method used has been described in detail elsewhere (McNatty et al. 2005a).

Thymidine incorporation assays

All cell incubations were carried out at 37 °C under 5% CO2 in air with 95% humidity. For the oocyte titration experiments, the appropriate number of DO and 20,000 live GC were co-incubated with 0, 8, 32 or 64 DO of the same species and across species. In the growth factor neutralisation experiments, 30 μl of M199 media containing 32 DO were added to each test well together with 5 μl of the appropriate antibody. The addition of 20 μl of M199 media containing 20,000 GC resulted in a final volume of 55 μl/well. The antibodies tested were MABs specific for either GDF9 (Mab47B) or BMP15 (Mab61A, Mab3A/A) or a control MAB against a nematode antigen (MabPAB1). Control wells containing DO with GC but no antibody or GC without DO were included in each incubation experiment. The Mab47B antibody was made against the ovine GDF9 mature protein sequence SEYFKQFLFQNEC, which has 100% sequence homology with mice. This sequence also has a 93% homology with the corresponding rat sequence (SEYFRQFLFQNEC). Moreover, this antibody has previously been used for immunoneutralisation studies of GDF9 in vitro and the antibody does not cross-react with BMP15 (McIntosh et al. 2008). The Mab61A antibody against BMP15 was generated after immunization of mice against an E. coli-derived sheep BMP15 mature protein and found to be effective in immunoneutralisation studies in sheep and not to cross-react with GDF9 (McNatty et al. 2005a). From peptide mapping studies, the MAB appears to be directed against an N-terminal sequence on the mature protein sequence, QAGSIASEVPGPSQ (unpublished data; amino acid differences in bold). This sequence has a 64% homology with the corresponding rat BMP15 sequence, QTCGIASDVPCPSQ (amino acid differences are in bold). However, there are four homologous amino acids in a row (italicised) and previous studies with BMP15 and GDF9 antibodies indicate that a 27% homology can be sufficient for antibody recognition of ligand (McNatty et al. 2007). To validate the efficacy of the Mab61A antibody to immuno-neutralise rat BMP15, a 293-derived recombinant αGDF9 (66 ng/ml; McNatty et al. 2005a) and 293-derived recombinant rBMP15 (6.5 ng/ml) were either added alone or together with rat GC; these experiments were performed without antibody, with the control (PAB1) antibody (3.4 μg/ml) or with Mab61A (3.4 μg/ml) as described earlier (n=4 replicate experiments). In all experiments involving measures of 3H-thymidine incorporation, the method used has been described in detail elsewhere (McNatty et al. 2005a).

Western blotting

The western blotting technique for the GDF9 and BMP15 proteins has been described in detail elsewhere (McIntosh et al. 2008). The samples (100–500 rat or sheep oocytes) were incubated for 24 h at a concentration of 2 oocytes/μl. Thereafter, the incubation media devoid of oocytes were collected into 0.2 ml PCR tubes and 50 μl of fresh M199 media were added to the oocytes. Both the incubation media

Table 1 A and B: probe sequences used in rat and sheep multiplex QPCR.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
<th>Probe</th>
</tr>
</thead>
<tbody>
<tr>
<td>(A) Rat</td>
<td>[Cy5]CCATGCAACCTCTGTCACAGATCGGAGG</td>
<td>[BHQ3]</td>
<td>[BHQ1]</td>
</tr>
<tr>
<td>RPL19</td>
<td>[FAM]CAGCTCTGACAACTCGCTTCTCTC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gdf9</td>
<td>[HEX]CACTCTGAACAACTCCGCTGCTTC</td>
<td>[BHQ1]</td>
<td></td>
</tr>
<tr>
<td>BMP15</td>
<td>[6FAM]AGTCTCAGCCTCAGATTCCAACGCAGTCCTA</td>
<td>[BHQ1]</td>
<td></td>
</tr>
<tr>
<td>(B) Sheep</td>
<td>[Cy5]TTCTCATCTCCTCCTACCCAGTACACCTCG</td>
<td>[BHQ3]</td>
<td></td>
</tr>
<tr>
<td>RPL19</td>
<td>[FAM]AGTCTCAGCCTCAGATTTCCAACGCAGTCCTA</td>
<td>[BHQ1]</td>
<td></td>
</tr>
<tr>
<td>GDF9</td>
<td>[6FAM]CACTCTGAACAACTCCGCTGCTTC</td>
<td>[BHQ1]</td>
<td></td>
</tr>
<tr>
<td>BMP15</td>
<td>[HEX]CACTCTGAACAACTCCGCTGCTTC</td>
<td>[BHQ1]</td>
<td></td>
</tr>
</tbody>
</table>

Table 2 Forward and reverse primer concentration in nanomolar for rat and sheep multiplex QPCR.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Rat</th>
<th>Sheep</th>
</tr>
</thead>
<tbody>
<tr>
<td>Forward</td>
<td>Reverse</td>
<td>Probe</td>
</tr>
<tr>
<td>GDF9</td>
<td>200</td>
<td>100</td>
</tr>
<tr>
<td>BMP15</td>
<td>300</td>
<td>200</td>
</tr>
<tr>
<td>RPL19</td>
<td>300</td>
<td>200</td>
</tr>
</tbody>
</table>
and the oocyte lysate samples contained a 25-fold dilution of the protease inhibitor cocktail (Roche Diagnostics) and were stored at −20 °C until processing. For these experiments, the MABs Mab37A and Mab47B were used to detect GDF9 in sheep and rat experiments respectively. The Mab37A antibody has previously been shown to be specific to ovine GDF9 (McNatty et al. 2005a). For the detection of BMP15 in both sheep and rat experiments, Mab61A antibody was used. The ability of Mab61A to recognise rat BMP15 protein was also tested using another MAB, Mab3A/A (generously supplied by Dr N Groome, Oxford Brookes University, Oxford, UK). This antibody was raised against a 29 amino acid sequence at the c-terminus end of human BMP15. This sequence shares an 83% homology with rat BMP15. The amino acid sequences are VPYKYPVPSVLMIEANGSILYKEYGMIA (human BMP15) and VYPYKFLPMSILLIEANGSILYKEYGMIA (rat BMP15; the amino acid differences are indicated in bold). Mab3A/A has routinely been used in our laboratory to detect mouse BMP15 (Reader et al. 2011) and shares a 93% homology with rat BMP15 (VPYNFLPMSILLIEANGSILYKEYGMIA; mouse sequence; the amino acids that differ to the rat sequence are indicated in bold). For the GDF9 reference standard, a 293H cell-derived ovine GDF9 was used as a positive control. For the blocking experiments, an E. coli-derived ovine GDF9 mature protein was used. For ovine BMP15, the reference standard was a 293H cell-derived ovine BMP15 and for the ovine blocking experiment, E. coli-derived ovine BMP15 mature protein was used. For the rat BMP15 studies, both a 293H cell-derived rat BMP15 and a 293H cell-derived ovine BMP15 were used as reference standards and blocking was performed with either an E coli-derived ovine BMP15 or a mouse BMP15 preparation (McNatty et al. 2005a, McIntosh et al. 2008).

### Analyses of GDF9 and BMP15 mRNA

The multiplex qPCR methodology used in this study has been described in detail by Crawford et al. (2011). Total RNA from frozen pools of 32 oocytes per time point (n = 5–6) was extracted using the ArrayPure Nanoscale RNA purification kit (Epicentre Biotechnologies, Madison, WI, USA) according to the manufacturer’s instructions. An in-house 0.1 M Tris–HCl buffer with 0.5 M EDTA (pH 8.0) was used to reconstitute the precipitated total RNA. All other specialised reagents were supplied in the kit. The synthesis of cDNA was carried out with the SuperScript Vilo cDNA Synthesis Kit (Invitrogen) following the manufacturer’s instructions. The primer and probe sequences for rat and sheep are shown in Table 1, and their optimised concentrations are shown in Table 2. The efficiencies for each qPCR reaction were ≥93%. Quantification of samples using the ΔΔCT method (Livak & Schmittgen 2001) has been reported elsewhere (Crawford et al. 2011). The expression levels of GDF9 and BMP15 in the DO were relative to a calibrator sample (cDNA from a rat or ovine ovary). Although the housekeeping gene (RPL19) was included in every triplex reaction, the values were not corrected for RPL19 but expressed as total expression of oocyte GDF9 or BMP15. The ratios of GDF9:BMP15 mRNA in individual oocytes was calculated by 1:2−(ΔΔCTGDF9+CBBMP15).

### Statistical analyses

For the 3H-thymidine uptake studies, the results from individual experiments were averaged and a one-way ANOVA was performed. If differences were observed from ANOVA, the Bonferroni’s post-hoc test was used to test for differences between individual group means. If the data were not normally distributed, they were naturally log-transformed before analyses. For non-normally distributed data, the Kruskal–Wallis non-parametric test was also undertaken. Means that differed by P < 0.05 were considered to be significantly different from one another. For the antibody immuno-neutralisation studies, the means for the incubations without antibody (no antibody control) were arbitrarily assigned a value of 1. Thereafter, the fold change for every GDF9 or BMP15 antibody treatment relative to the no antibody control was compared to the fold-change for the non-specific antibody control using the Student’s t-test. To examine the relationship between the relative expression levels for GDF9 and BMP15 mRNA, the cycle threshold (Ct) values for each oocyte was subjected to linear regression analyses.

### Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

### Funding

This research was supported by the New Zealand Foundation for Research, Science and Technology (C10X0308), the Royal Society of New Zealand Marsden Fund (08-VUW-010) and an AgResearch PhD Scholarship to J Lin.

### Acknowledgements

The authors wish to thank Prof. Sue Schenk and Mr Richard Moore (Department of Psychology, Victoria University of Wellington) for the supply of rats used in these experiments and the staff at Taylor Preston Meatworks, Wellington, for the supply of sheep ovaries. They also wish to thank Prof. Olli Ritvos (University of Helsinki, Finland) for the transfected 293H cell lines and Mr Steve Lawrence and Ms Andrea Western for the supply of the recombinant E. coli and 293H-derived GDF9 and BMP15 proteins.

### References


www.reproduction-online.org


www.reproduction-online.org


Received 27 October 2011
First decision 21 December 2011
Revised manuscript received 23 August 2012
Accepted 10 September 2012